Quotient (NASDAQ:QTNT) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Quotient (NASDAQ:QTNT – Get Rating) in a research report sent to investors on Tuesday. The firm issued a hold rating on the stock.

Separately, The Goldman Sachs Group cut their price objective on Quotient from $3.00 to $1.50 and set a neutral rating for the company in a report on Tuesday, April 19th.

QTNT opened at $0.40 on Tuesday. The stock has a 50-day moving average price of $0.47 and a 200-day moving average price of $1.21. Quotient has a 12-month low of $0.27 and a 12-month high of $4.25. The stock has a market capitalization of $41.04 million, a P/E ratio of -0.30 and a beta of 2.72.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Citigroup Inc. boosted its holdings in shares of Quotient by 114.2% in the 3rd quarter. Citigroup Inc. now owns 10,992 shares of the company’s stock worth $26,000 after purchasing an additional 5,861 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Quotient by 70.5% during the 4th quarter. ProShare Advisors LLC now owns 17,142 shares of the company’s stock valued at $45,000 after acquiring an additional 7,086 shares during the period. Balyasny Asset Management LLC purchased a new stake in Quotient during the 3rd quarter valued at about $28,000. Jefferies Group LLC purchased a new stake in Quotient during the 3rd quarter valued at about $35,000. Finally, Squarepoint Ops LLC purchased a new stake in Quotient during the 3rd quarter valued at about $49,000. Hedge funds and other institutional investors own 77.47% of the company’s stock.

Quotient Company Profile (Get Rating)

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening.

Recommended Stories